# Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

> **NCT00428389** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 262 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rivastigmine 5 cm^2 transdermal patch
- **DRUG:** Rivastigmine 10 cm^2 transdermal patch

## Key facts

- **NCT ID:** NCT00428389
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 262 (ACTUAL)
- **Last updated:** 2014-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428389, "Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00428389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*